SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as the community keenly anticipates 48-week IMPACT Phase 2b trial data for its MASH treatment, Pemvidutide, following reports of improved antifibrotic activity and favorable tolerability. Excitement is high around the FDA's support for advancing to a Phase 3 trial and the integration of AI-assisted pathology reads, driving intense speculation about potential strategic partnerships or acquisitions.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is a trending topic following its latest financial results, which indicated pressure on gross margins and a decline in sales within the crucial China market, leading to a divided investor sentiment. The community is actively debating whether current valuations present a 'buy the dip' opportunity for the iconic brand or if intensifying competition and strategic challenges signal a prolonged period of underperformance.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending as investors hotly debate a lawsuit filed against alleged manipulators, with strong opinions on whether management is effectively addressing stock undervaluation through promised buybacks. The community discussion also centers on the phased rollout of a large AI data center contract and a recent Nobel Sustainability Trust nomination, as many question market integrity and management's actions amidst persistent share price pressure.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is actively discussed following the executive order to reclassify cannabis to Schedule III, a significant policy shift that the company is leveraging to advance its U.S. medical cannabis operations through its newly formed Tilray Medical USA unit. Despite sector-wide volatility interpreted by some as a "sell the news" event, many in the community emphasize the long-term benefits for profitability and institutional investment stemming from this historic regulatory change.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending due to its announced merger with fusion power firm TAE Technologies, valued at over $6 billion. This strategic pivot into fusion energy, with its long-term potential for powering AI, is generating significant discussion among investors, ranging from excitement for a potential industry breakthrough to skepticism over its viability and concerns about the company's past volatility and valuation.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as new developments in its autonomous driving technology, including an in-house AI chip and expanded hands-free driving capabilities, are re-energizing investor conversation. The community is actively discussing how these advancements, alongside the anticipated R2 vehicle, position Rivian as a significant player evolving beyond a traditional EV manufacturer, fueling expectations of substantial growth.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata (INOD) is gaining significant attention as investors keenly anticipate a transformative strategic partnership, potentially with a major government or military contractor, expected to be announced before year-end. While bulls are confident in a substantial rally from current oversold conditions, citing INOD's strong fundamentals in the booming AI data training sector, skeptics voice concerns over past delays and the stock's ability to overcome broader market headwinds and institutional buying limitations.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is experiencing significant volatility driven by an upcoming shareholder vote on increasing authorized shares, fueling concerns about potential dilution, and a major investor's planned divestment. Despite its unique NRC-certified SMR technology being touted as crucial for AI's immense energy demands, community sentiment remains sharply divided between those labeling it a "scam" due to recent declines and others seeing a "generational buying opportunity" in the long-term nuclear power narrative.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber, Inc. (WYFI) is trending due to a substantial new colocation agreement with Nscale for its NC-1 AI data center campus, which has ignited significant community excitement. Investors are actively discussing the deal's improved long-term revenue visibility, the potential for a short squeeze, and how the company's limited share float could drive considerable upside. This positions WhiteFiber as a key player in the rapidly expanding market for AI-ready data center capacity.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx is trending following stronger-than-expected financial results, driven by ongoing cost-cutting and network transformation initiatives. The community is actively debating the significance of the earnings beat and raised outlook, with bulls anticipating further upside, while others express caution regarding potential impacts from expiring trade exemptions and fierce industry competition. The immediate market reaction has been a key talking point, with some noting limited sustained gains despite the positive report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ESSA Announces Completion of Arrangement with XenoTherapeutics

ESSA Announces Completion of Arrangement with XenoTherapeutics ESSA Announces Completion of Arrangement with XenoTherapeutics PR Newswire SOUTH SAN FRANCISCO, Calif., USA and VANCOUVER, BC, Canada...

Shares of Essa Pharma, Inc. (<a class="mention" data-mention="$EPIX" data-symbol-id="EPIX" href="https://stocktwits.com/symbol/EPIX" target="_blank">$EPIX</a>) plummeted 70% on Friday morning after the company announced it would end its Phase 2 study of masofaniten, its lead drug candidate for prostate cancer.&nbsp;Essa’s decision follows an interim analysis indicating that the study was unlikely to meet its primary endpoint, a move aimed at prioritizing patient benefit and safety.&nbsp;CEO David Parkinson noted that the trial’s emerging efficacy profile for masofaniten, when combined with enzalutamide, was insufficient to justify continuation.Richard Glickman, Chairman of Essa’s Board, confirmed that the company is shifting focus to preserve capital, initiating a strategic review to explore options for maximizing shareholder value.&nbsp;JonesResearch analyst Soumit Roy downgraded Essa Pharma to ‘Hold’ from ‘Buy,’ saying “we were wrong in our assessment of masofaniten's potential.”&nbsp;Roy also anticipates the stock to trade at a 40%-50% discount to its cash per share, currently $2.64, until further guidance from management.<figure class="image"><a href="https://stocktwits.com/symbol/EPIX"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_01_at_9_42_09_AM_25b012ad7e.png" alt="Screenshot 2024-11-01 at 9.42.09 AM.png" width="1314" height="320"></a><figcaption>EPIX sentiment and message volume on Nov. 1 as of 9:45 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment turned ‘extremely bearish’ (9/100), the lowest in a year, with several users questioning the company’s pipeline viability.&nbsp;Some predicted a continued slide, with expectations of the stock trading below $1 as large shareholders exit their positions for tax write-offs.<stembedurl>https://stocktwits.com/StarLord13/message/590874905</stembedurl><stembedurl>https://stocktwits.com/elmono/message/590874567</stembedurl>Essa’s stock is down about 20% year-to-date as of Thursday’s close.&nbsp;Shares of the company are currently trading at their lowest level in over two years.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next: <a href="https://stocktwits.com/news-articles/markets/equity/wayfair-stock-rises-on-q3-earnings-beat/cJEYA3ARBk">Wayfair Thrills Retail Crowd As Stock Soars Premarket On Big Q3 Earnings Beat</a>

Shares of Essa Pharma are currently trading at their lowest level in over two years.

Essa Pharma Stock Crashes After Lead Drug Candidate Trial Flops: Retail Hopes Fade

Richard Glickman, Chairman of Essa’s Board, confirmed that the company is shifting focus to preserve capital, initiating a strategic review

Equity

Richard Glickman, Chairman of Essa’s Board, confirmed that the company is shifting focus to preserve capital, initiating a strategic review


ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

Essa Pharma Inc

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

EPIX
Essa Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EPIX News

EPIXEssa Pharma Inc